Signals, Powered By EquityPandit
An agreement has been signed by Dr Reddy’s Laboratories with Teva Pharmaceutical and an affiliate of Allergan PIc for buying a portfolio of eight abbreviated new drug applications (ANDAs) in the US for USD 350 million (around Rs 2,300 crore) in cash.
Dr Reddy’s Laboratories has said in a statement that the portfolio being acquired is a mix of filed ANDAs pending approval and an approved ANDA and comprised of complex generic products across diverse forms.
It added that the combined sales of the branded versions of the products in the US is around USD 3.5 billion.
